Skip to main content
Premium Trial:

Request an Annual Quote

Starting Again on Alzheimer's

Nobel Prize-winning scientist Paul Greengard has discovered a new way for researchers to target Alzheimer's disease. Beta amyloid, the plaque that builds up in the brains of Alzheimer's patients, has long been targeted by researchers. Now Greengard has discovered a new protein that is needed to make beta amyloid, reports the New York Times' Gina Kolata. Many Alzheimer's drugs currently being studied target the enzyme gamma secretase, which helps make beta amyloid. However, Kolata says, gamma secretase also serves crucial functions in the body, and efforts to block it have caused other problems. Greengard's "gamma secretase activating protein" tells the enzyme to make beta amyloid, and since it's used by the enzyme for this purpose only, suppressing it doesn't have any effect on other gamma secretase activity, Kolata says. Greengard has so far only experimented with blocking this new protein in mice, but has had some encouraging results, which appear in Nature this week.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.